This inventor holds 3 USPTO granted patents and 1 published patent application. Top assignees: Ciba-Geigy Corporation, Novartis Corporation. Active years: 1995-1997.
Company Filing History:
Years Active: 1995-1997
Title: Stephen P Collingwood: Innovator in Oligonucleotide Analogues
Introduction
Stephen P Collingwood is a notable inventor based in Westhoughton, GB, recognized for his innovative contributions to the field of oligonucleotide analogues. With a total of three patents to his name, he has made significant strides in pharmaceutical chemistry, demonstrating remarkable expertise in nucleoside and phosphinate compounds.
Latest Patents
Among his recent innovations, Collingwood holds patents for the following inventions:
1. **Oligonucleotide analogues** - This patent describes a dinucleotide analogue of a specific formula, where both B¹ and B² represent independently chosen monovalent nucleoside base radicals.
2. **Nucleoside phosphinate compounds and compositions** - This patent outlines a compound formula characterized by multiple variables that include hydrogen, aliphatic, aromatic and cycloaliphatic radicals, along with various protective groups. The methods for preparation and potential pharmaceutical applications of these compounds are also elaborated in the patent disclosure.
Career Highlights
Stephen P Collingwood has worked with prominent companies, including Ciba-Geigy Corporation and Novartis Corporation. His tenure at these organizations has allowed him to refine his skills and contribute to the advancement of chemical sciences, particularly concerning nucleic acid research.
Collaborations
Throughout his career, Collingwood has collaborated with esteemed colleagues such as Anthony D Baxter and Eric K Baylis. These partnerships have fostered an environment of innovation and creativity, leading to the accomplishment of significant breakthroughs in his field.
Conclusion
Stephen P Collingwood's work exemplifies the impact of dedicated research and innovation in the pharmaceutical industry. With his impressive portfolio of patents and collaborative endeavors, he continues to push the boundaries of science, paving the way for future developments in oligonucleotide technologies.